948 related articles for article (PubMed ID: 27697638)
21. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z
Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909
[TBL] [Abstract][Full Text] [Related]
22. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.
Albuquerque RJ; Hayashi T; Cho WG; Kleinman ME; Dridi S; Takeda A; Baffi JZ; Yamada K; Kaneko H; Green MG; Chappell J; Wilting J; Weich HA; Yamagami S; Amano S; Mizuki N; Alexander JS; Peterson ML; Brekken RA; Hirashima M; Capoor S; Usui T; Ambati BK; Ambati J
Nat Med; 2009 Sep; 15(9):1023-30. PubMed ID: 19668192
[TBL] [Abstract][Full Text] [Related]
23. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?
Goyal S; Chauhan SK; El Annan J; Nallasamy N; Zhang Q; Dana R
Arch Ophthalmol; 2010 Jul; 128(7):819-24. PubMed ID: 20625040
[TBL] [Abstract][Full Text] [Related]
24. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
25. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
26. Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model.
Hu J; Ye H; Fu A; Chen X; Wang Y; Chen X; Ye X; Xiao W; Duan X; Wei Y; Chen L
Int J Cancer; 2010 Nov; 127(10):2455-66. PubMed ID: 20162567
[TBL] [Abstract][Full Text] [Related]
27. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
[TBL] [Abstract][Full Text] [Related]
28. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
30. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
31. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
32. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis.
Burton JB; Priceman SJ; Sung JL; Brakenhielm E; An DS; Pytowski B; Alitalo K; Wu L
Cancer Res; 2008 Oct; 68(19):7828-37. PubMed ID: 18829538
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
34. New model of in-situ xenograft lymphangiogenesis by a human colonic adenocarcinoma cell line in nude mice.
Sun JJ; Jing W; Ni YY; Yuan XJ; Zhou HH; Fan YZ
Asian Pac J Cancer Prev; 2012; 13(6):2823-8. PubMed ID: 22938466
[TBL] [Abstract][Full Text] [Related]
35. Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis.
Nakao S; Zandi S; Hata Y; Kawahara S; Arita R; Schering A; Sun D; Melhorn MI; Ito Y; Lara-Castillo N; Ishibashi T; Hafezi-Moghadam A
Blood; 2011 Jan; 117(3):1081-90. PubMed ID: 20705758
[TBL] [Abstract][Full Text] [Related]
36. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis.
Durré T; Morfoisse F; Erpicum C; Ebroin M; Blacher S; García-Caballero M; Deroanne C; Louis T; Balsat C; Van de Velde M; Kaijalainen S; Kridelka F; Engelholm L; Struman I; Alitalo K; Behrendt N; Paupert J; Noel A
Nat Commun; 2018 Dec; 9(1):5178. PubMed ID: 30518756
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
38. Mirtron microRNA-1236 inhibits VEGFR-3 signaling during inflammatory lymphangiogenesis.
Jones D; Li Y; He Y; Xu Z; Chen H; Min W
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):633-42. PubMed ID: 22223733
[TBL] [Abstract][Full Text] [Related]
39. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Wen J; Fu AF; Chen LJ; Xie XJ; Yang GL; Chen XC; Wang YS; Li J; Chen P; Tang MH; Shao XM; Lu Y; Zhao X; Wei YQ
Int J Cancer; 2009 Jun; 124(11):2709-18. PubMed ID: 19219913
[TBL] [Abstract][Full Text] [Related]
40. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
